Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by mercedesmanon Aug 16, 2022 10:33am
208 Views
Post# 34899201

RE:Financing

RE:Financing
Quacker wrote: If there is financing that is needed there are two options: 1. Go to the Bank and get a Line of credit using the contracts from ARC and Dept of Veterans. 2. Go to the more likely source Baxter and ask them to give their 2nd tranche a little earlier. We have signed a contract with them and now seeing what Dialco has done with Arc and Veteran 's Dept, it might be to their benefit. If there is a financing coming out in the way of warrants, first right should go out to the existing shareholders (we have kept the company a float for all these years). l would love to see a Shareholder Ombudsman selected to sit on the Board and responsible for sitting on the Compensation Committee in charge of looking at Management Compensation. Also, should be in charge of shareholder updates. I invested in this company as they were looking to get rid of sepsis in North America and still believe we are on the right track. I remember the cardiac discovery so you know I am a Long.


Nice Post !

There are actually several forms of alternative financing that could fill the kitty, including:

1. Debt * -  (always the cheapest form of financing) *  on the strength of valid orders/contracts.
2. Convertable Debt.
3. Accelerated Baxter payments
4. Deposits on future SAMI units to be sold to ARC and VA (perhaps discounted in return for advance deposits)
5. Distribution Agreement Advance (for potential future Dialco partners) ala Baxter
6. Announce a spin-off Dialco (will also appreciate the SP) and perhaps, at the same time, sell a small equity portion to a Major, or other Interested party.

* Next to improving the SP by making the stock better known via PR/Marketing, more US exposure, etc.    Would allow for more funds inflow for say.50 warrant execution.  At the very least, less dilutive eqty raises with a supported/healthier SP.

MM




<< Previous
Bullboard Posts
Next >>